In Brief: PerSeptive Biosystems
This article was originally published in The Gray Sheet
PerSeptive Biosystems: Plans to acquire its independent R&D vehicle PerSeptive Technologies II Corp. Under a definitive agreement announced Nov. 1, Biosystems will commence an offer to exchange one Biosystems share and a Biosystems share purchase warrant for each of the 2.645 mil. outstanding units of PTC-II. Formed in December 1993 ("The Gray Sheet" Nov. 22, 1993, p. 14), PTC-II contracted with Biosystems "to engage in the research and development of products in the fields of clinical diagnostics, drug screening, DNA and protein sequencing and DNA and peptide synthesis," the firm states. Biosystems now plans to begin to commercialize the technologies...
You may also be interested in...
Butterfly Network chose SPAC route with Longview Acquisition Corp. to scale its business and expand into the home market in 2021.
Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.
With Warp Speed Decisions Already Made, Transitioning To Biden Admin Should Be No Trouble, Slaoui Says
As vaccines near availability, Moncef Slaoui says his full-time role at OWS may be ending. He has not met with the Biden Transition team, but notes that other Warp Speed officials have.